Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 164Lung Neoplasms 61Small Cell Lung Carcinoma 24Neoplasms 10NSCLC 9Mesothelioma, Malignant 9Breast Neoplasms 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Melanoma 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Esophageal Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Mesothelioma 4Kidney Neoplasms 4Brain Neoplasms 4Sarcoma 3Pleural Effusion, Malignant 3Liver Neoplasms 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Thymus Neoplasms 2Thymoma 2Small Cell Lung Cancer Limited Stage 2Skin Neoplasms 2

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Non-small Cell Lung Cancer × Drug Therapy × Thoracic × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡